Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
27 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CABINET DU DR CATHERINE PASQUET-DUMONTEIL
3 AVENUE DE CHOISY, 75013 PARIS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Health science reports · 2024
AbstractBackgroundIn this study, we investigated whether the association of curcumin and docetaxel among advanced and metastatic breast cancer patients in first or second‐line treatment potentiated the objective response rate.Patients/MethodsA multicentre, randomized, open label, phase‐II study was conducted and included 42 patients from July 2009 to January 2017. The primary endpoint was the objective response rate of the docetaxel‐curcumin combination in comparison with docetaxel alone. The secondary endpoints were the assessment of clinical benefit, overall survival, time‐to‐progression, progression‐free survival, compliance, and safety. An interim analysis was planned to evaluate safety and efficacy.ResultsIn this interim analysis conducted on 37 patients (19 in the control group vs. 18 in the experimental group), no difference was observed for the objective response rate (p = 0.25, control 73.7% vs. experimental 55.6%). Concerning clinical benefit, overall survival and time‐to‐progression, we also failed to show any difference between the two arms. A slight tendency towards longer progression‐free survival at 12 months after randomization was observed in the curcumin group (65.5% vs. 41.4%) but this difference did not reach significance (p = 0.14).ConclusionIn this study, we showed for the first time that adding oral curcumin for advanced and metastatic breast cancer patients treated with first or second‐line docetaxel was not efficacious, although safe. Consequently, this study was stopped for reasons of futility. Further studies with a larger number of patients, a different curcumin preparation, a longer treatment period and a pharmacokinetic evaluation of curcumin are needed to explore the real efficacy of this compound.
Journal of leukocyte biology · 2024
Abstract Mepolizumab, an anti-interleukin-5 antibody, has been proven a safe and effective glucocorticoid (GC)-sparing drug for many patients with nonclonal hypereosinophilic syndrome (HES) and is now approved in many countries. It remains unclear, however, which patients are most likely to benefit from therapy and whether the currently approved dosing regimen is appropriate for all. This observational retrospective study included all patients with HES who were enrolled in the MHE104317 compassionate use program (CUP) in our center. Patient and disease characteristics, mepolizumab dosing, and both clinical and hematological responses to treatment were collected from medical files. Treatment responses and mepolizumab dosing requirements were analyzed according to disease characteristics. Eighteen patients with HES were enrolled in the CUP, of whom nine are still on treatment. The median duration of exposure to mepolizumab was 45 mo (maximum 18 yr). A lower number of affected organs, requirement for GC dosing ≤10 mg prednisone-equivalent, and single-organ HES were associated with a higher likelihood of complete response. Lymphocytic variant HES (L-HES) was less treatment-responsive, leading to withdrawal and/or requiring higher mepolizumab dosing to achieve some degree of disease control. In contrast, all patients with single-organ disease had a complete response that could often be maintained despite increasing between-dose intervals. Few potentially treatment-related adverse events were observed despite prolonged exposure. This study confirms the efficacy and safety of mepolizumab in HES, although patients with L-HES rarely experience a complete response. In contrast, patients with single-organ disease affecting the lungs are often super-responders, and decreasing mepolizumab dosing may be attempted.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of orthodontic science · 2026 · Journal Article
Catherine S, Harshitha V, Surendran S, Shetty P, et al.
Materials (Basel, Switzerland) · 2026 · Journal Article
Catherine JH, Jeanneau C, Iasio R, Lan R, et al.
European journal of obstetrics, gynecology, and reproductive biology · 2026 · Journal Article
Louise A, Guillaume C, Marie F, Catherine F, et al.
Discover nano · 2025 · Journal Article
Ramayanam NR, Bukke SPN, Moka MK, Dehingia H, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference · 2025 · Journal Article
G A, C G, C J M, B L, et al.
Therapeutic advances in gastroenterology · 2025 · Journal Article
Juliette B, Caroline TP, Mathurin F, Guillaume B, et al.
The Journal of allergy and clinical immunology · 2025 · Journal Article
Catherine J, Karimi S, Dewispelaere L, Lelubre C, et al.
Journal of leukocyte biology · 2024 · Journal Article
Coussement G, Catherine J, Roufosse F
Journal of endourology · 2025 · Journal Article
Catherine C, Pokharkar A, Kandpal DK, Yadav P, et al.
Environmental health : a global access science source · 2025 · Journal Article
Barrea C, Dufour P, Catherine P, Charlier C, et al.
European journal of pediatrics · 2024 · Journal Article
Yıldız Ç, Küçükali B, C SSB, Şenol PE, et al.
European journal of pediatrics · 2024 · Journal Article
Cureus · 2025 · Case Reports
C P, Ann Jose J, Verma G, Priya V L, et al.
Journal of endourology · 2025 · Journal Article
Catherine C, Pokharkar A, Kandpal DK, Yadav P, et al.
International journal of surgery case reports · 2025 · Case Reports
Noémie VH, Catherine V, Laure M, Stephen T, et al.
Child abuse & neglect · 2025 · Journal Article
Catherine NLA, Zheng Y, Xie H, Boyle M, et al.
BMJ open · 2025 · Journal Article
Catherine NLA, MacMillan H, Jack S, Zheng Y, et al.
Health science reports · 2024 · Journal Article
Judith PJ, Maureen B, Mélanie P, Fabrice K, et al.
Seizure · 2025 · Journal Article
Annalise W, Anita H, Judith D, Sereena R, et al.
Marine environmental research · 2025 · Journal Article
Amélie S, Salomé C, Xuan-Minh-Ai N, Abdessalem S, et al.
International journal of surgery case reports · 2025 · Case Reports
Noémie VH, Catherine V, Laure M, Stephen T, et al.
Infant mental health journal · 2026 · Journal Article
Catherine E, Palomino C, Perry D, Eckley L, et al.
Indian journal of occupational and environmental medicine · 2026 · Journal Article
Catherine AA, Jiten R, Deborah MA, Naveen R
BMJ open · 2025 · Journal Article
Catherine NLA, MacMillan H, Jack S, Zheng Y, et al.
Seizure · 2025 · Journal Article
Annalise W, Anita H, Judith D, Sereena R, et al.
International journal of surgery case reports · 2025 · Case Reports
Noémie VH, Catherine V, Laure M, Stephen T, et al.
BMJ open · 2025 · Journal Article
Kurz M, Guerra-Alejos BC, Hossain MB, Min JE, et al.
Child abuse & neglect · 2025 · Journal Article
Catherine NLA, Zheng Y, Xie H, Boyle M, et al.
Age and ageing · 2025 · Journal Article
Manuel RFJ, Marie-Jeanne K, Fanny B, Stephanie DL, et al.
European journal of pediatrics · 2024 · Journal Article
Yıldız Ç, Küçükali B, C SSB, Şenol PE, et al.
Scientific reports · 2026 · Journal Article
Chiara K, Sabrina T, Michael H, Catherine W
La Revue du praticien · 2025 · Journal Article
Catherine H
Age and ageing · 2025 · Journal Article
Manuel RFJ, Marie-Jeanne K, Fanny B, Stephanie DL, et al.
Infant mental health journal · 2026 · Journal Article
Catherine E, Palomino C, Perry D, Eckley L, et al.
Cureus · 2025 · Case Reports
Lakshme I, C A, Senthil N, Pandurangan V
Cureus · 2026 · Case Reports
R S, Nanda M S, Adalarasan S, Subramanian Y, et al.
Abdeljalil Z, Raphaël A, Catherine C, Kévin B